Minimum age of 11 set for UK puberty blocker trial

• Minimum age of 11 years established for UK puberty blocker clinical trial participation, reflecting regulatory requirements for research involving gender-questioning children
• Trial represents formal evaluation of puberty-blocking drug safety and efficacy in this population, addressing the evidence gap in paediatric gender medicine
• Age threshold aligns with developmental considerations and ethical frameworks governing research participation in minors with evolving gender identity

Gender-questioning children will have to be at least 11 years old to take part in a clinical trial of puberty-blocking drugs.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.